Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
about
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseasesNovel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancerIntraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancerAndrogens and prostate diseaseIntraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.New developments in the medical management of prostate cancer.Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.The different reduction rate of prostate-specific antigen in dutasteride and finasteride.Role of 5α-reductase inhibitors in benign prostatic diseases.Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study.Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia.Regulation of androgen receptor signaling in prostate cancer.Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate CancerRole of 5 alpha-reductase inhibitors in the management of prostate cancer.The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.Androgen receptor: role and novel therapeutic prospects in prostate cancer.Emerging drugs for prostate cancer.Early dutasteride monotherapy in men with detectable serum prostate-specific antigen levels following radical prostatectomy: A prospective trial.5α-reductase type 3 enzyme in benign and malignant prostate.Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum.Targeting 5α-reductase for prostate cancer prevention and treatmentProstate cancer detection after a negative prostate biopsy: lessons learnt in the Cleveland Clinic experience.Hair loss and herbs for treatment.Effect of Discontinuation of Tamsulosin in Korean Men with Benign Prostatic Hyperplasia Taking Tamsulosin and Dutasteride: An Open-Label, Prospective, Randomized Pilot Study.A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia.Effect of dutasteride on the expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in rat and human prostate tissue.Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume.Is There a Future for Chemoprevention of Prostate Cancer?Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatment.The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor, 5α-reductase 1 and 5α-reductase 2 in TRAMP mouse prostatesA dual 5α-reductase inhibitor dutasteride caused reductions in vascular density and area in benign prostatic hyperplasia.Application of transrectal ultrasound-guided repeat needle biopsy in the diagnosis of prostate cancer in Chinese population: A retrospective study.Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride.Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy.Prognostic influence of 5 alpha reductase inhibitors in patients with localized prostate cancer under active surveillance.
P2860
Q21285041-071AC76D-5090-4905-B233-22FB7F27FA3AQ24299807-94B8100D-9F4E-4FC5-A4A4-E20E0FB27CF8Q27005840-26013FF9-95DE-4D96-A53B-42DE87288EB8Q27010093-496E9AA1-F500-4DA2-8FFF-585D6A9CB95EQ27690719-4B629DBD-D01C-4E91-9068-52C3A5061CB6Q33566738-786ADA54-0625-4197-B1D2-476FDAA47B70Q33658285-194477BF-D179-45A7-93FC-A50A1AF825BBQ34239009-5C12959F-82E3-4CA6-A0D6-8A8C12AA5779Q34254296-327006B6-05B2-4AF3-91AE-153995318990Q34619574-61E36E55-07A1-469C-AC63-EC3FD9ADCDAAQ35808841-3333529A-085E-4397-86A4-02BE1DABA7F2Q36066106-74127315-763B-47BA-A6E0-BD1A6DAF76CBQ36066149-C94074E1-4233-46AC-803E-4B9EB12E7362Q36434305-02785FC0-F436-4D2A-8E04-8A7C7D045744Q37009071-BB91B8A0-F045-4A68-8BC3-FC4051A5EC1FQ37018960-479A13A4-8977-400C-B558-C663C07FAD36Q37086672-D7B0F2E9-38CD-413F-94AE-9FE6942E2FADQ37256846-4ACFA65F-83E8-4A79-9FA5-E56D6A5125A5Q37570555-475A3448-4EBC-4AB0-BDC7-B0BB9F8C4050Q37671710-06995F3E-0812-41E3-8E03-548F606257F3Q37712234-1DFC2A8A-D697-4D98-921B-B69178EE661DQ37723393-8D38279A-9072-4EF9-BC62-7930C25DF820Q37882512-1953D38C-552F-49C5-BFCB-EAEA9FD04EF5Q37883012-60CF9C07-97E1-44A4-B0E9-2D164E46E8CCQ37892629-4B4A40EA-D527-4D0E-A60D-40A184F302C1Q38132839-9EA56297-2C1C-4726-AF40-D349FD58F866Q38466939-6CE1577A-88F7-4774-AF69-33A37B985C60Q38485721-DCB0786C-1490-4BB2-91A5-AB5B9E40AD42Q38490532-777F0780-EBD4-412B-BA85-32B987628E2EQ38736795-30A899E9-9E6A-419C-82E1-80CEA9868A89Q38878301-752885B2-E56B-4873-86BF-98A1F6082C92Q40045955-68B18A3A-9334-48CC-B86E-F90DDE356FACQ41118422-00AEA7E3-BCBB-412F-86B3-75821787157BQ42103713-CE4A1C6F-B4AD-474E-BA6F-2FA4DB8EAF48Q42363869-F5B0A589-820B-414D-AEC6-C757A2D86834Q46853931-DA635F0D-383D-4702-9F8F-80DA475D537AQ48608872-00D1D3A5-44E0-478D-9C57-8406365EE34FQ50045232-04C04940-2969-48F0-9B55-4740E664C2D6Q52670853-AC124FBD-C972-45FA-9A19-63FF300BED9B
P2860
Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Effect of the dual 5alpha-redu ...... regression in prostate cancer.
@ast
Effect of the dual 5alpha-redu ...... regression in prostate cancer.
@en
Effect of the dual 5alpha-redu ...... regression in prostate cancer.
@nl
type
label
Effect of the dual 5alpha-redu ...... regression in prostate cancer.
@ast
Effect of the dual 5alpha-redu ...... regression in prostate cancer.
@en
Effect of the dual 5alpha-redu ...... regression in prostate cancer.
@nl
prefLabel
Effect of the dual 5alpha-redu ...... regression in prostate cancer.
@ast
Effect of the dual 5alpha-redu ...... regression in prostate cancer.
@en
Effect of the dual 5alpha-redu ...... regression in prostate cancer.
@nl
P2093
P1476
Effect of the dual 5alpha-redu ...... regression in prostate cancer.
@en
P2093
Andriole GL
Humphrey P
Rittmaster RS
Trachtenberg J
P304
P356
10.1097/01.JU.0000136430.37245.B9
P407
P577
2004-09-01T00:00:00Z